নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - tivozanib hydrochloride monohydrate 1.5mg equivalent to 1340 microgram tivozanib - capsule - 1340 mcg - active: tivozanib hydrochloride monohydrate 1.5mg equivalent to 1340 microgram tivozanib excipient: gelatin   iron oxide yellow   magnesium stearate mannitol titanium dioxide   - fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (rcc) and for adult patients who are vegfr and mtor pathway inhibitor-na?ve following disease progression after one prior treatment with cytokine therapy for advanced rcc.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - tivozanib hydrochloride monohydrate 1mg equivalent to 890 microgram tivozanib - capsule - 890 mcg - active: tivozanib hydrochloride monohydrate 1mg equivalent to 890 microgram tivozanib excipient: gelatin   indigo carmine iron oxide yellow magnesium stearate mannitol titanium dioxide   - fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (rcc) and for adult patients who are vegfr and mtor pathway inhibitor-na?ve following disease progression after one prior treatment with cytokine therapy for advanced rcc.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - bacillus calmette-guerin 500 mcfu (range: 2-8x10e8 cfu) - powder for injection - 500 mcfu - active: bacillus calmette-guerin 500 mcfu (range: 2-8x10e8 cfu) excipient: ammonia solution asparagine citric acid monohydrate dibasic potassium phosphate ferric ammonium citrate glycerol zinc formate lactose magnesium sulfate - oncotice is used as a treatment of flat urothelial cell carcinoma in situ (cis) of the bladder, and as an adjuvant therapy after transurethral resection (tur) of a primary or relapsing superficial papillary urothelial cell carcinoma of the bladder stage ta (grade 2 or 3) or t1 (grade 1, 2 or 3). oncotice is only recommended for stage ta grade 1 papillary tumours when there is judged to be a high risk of tumour recurrence.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

biocelect new zealand ltd - salmonella typhi strain ty21a berna 2000 million organisms (minimum); salmonella typhi vaccine live attenuated 2000 million organisms (ty21a strain; minimum); salmonella typhi strain ty21a berna 2000 million organisms - modified release capsule - 2000 million organisms - active: salmonella typhi strain ty21a berna 2000 million organisms (minimum) excipient: ascorbic acid casein hydrolysate dibutyl phthalate diethyl phthalate erythrosine ethylene glycol gelatin hypromellose phthalate lactose fast flo iron oxide red iron oxide yellow lactose monohydrate magnesium stearate sucrose titanium dioxide active: salmonella typhi vaccine live attenuated 2000 million organisms (ty21a strain; minimum) excipient: ascorbic acid casein hydrolysate dibutyl phthalate diethyl phthalate erythrosine ethylene glycol gelatin hypromellose phthalate iron oxide red iron oxide yellow lactose magnesium stearate sucrose titanium dioxide active: salmonella typhi strain ty21a berna 2000 million organisms excipient: ascorbic acid diethyl phthalate erythrosine ethylene glycol gelatin hypromellose phthalate iron oxide red iron oxide yellow lactose magnesium stearate methanol methylene chloride protein hydrolysate sucrose titanium dioxide - vivotif oral is indicated for active immunisation against typhoid in adults and children above 6 years of age. effectiveness in children below 6 years of age is not known at present.

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

rebel distributors corp - salmonella enterica subsp. enterica serovar typhi (unii: 760t5r8b3o) (salmonella enterica subsp. enterica serovar typhi - unii:760t5r8b3o) - salmonella enterica subsp. enterica serovar typhi 2 [cfu] - vivotif (typhoid vaccine live oral ty21a) is indicated for immunization of adults and children greater than 6 years of age against disease caused by salmonella typhi . routine typhoid vaccination is not recommended in the united states of america. selective immunization against typhoid fever is recommended for the following groups: 1) travelers to areas in which there is a recognized risk of exposure to s. typhi , 2) persons with intimate exposure (e.g. household contact) to a s. typhi carrier, and 3) microbiology laboratorians who work frequently with s. typhi (7). there is no evidence to support the use of typhoid vaccine to control common source outbreaks, disease following natural disasters or in persons attending rural summer camps. not all recipients of vivotif will be fully protected against typhoid fever. vaccinated individuals should continue to take personal precautions against exposure to typhoid organisms. the vaccine will not afford protection against species of salmonella other than salmonella

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

curium us llc - indium in-111 pentetreotide (unii: m312jj6z32) (indium in-111 pentetreotide - unii:m312jj6z32) - pentetreotide 10 ug in 1 ml - octreoscan, after radiolabeling, is an agent for the scintigraphic localization of primary and metastatic neuroendocrine tumors bearing somatostatin receptors. none known.

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

aveo pharmaceuticals, inc. - tivozanib hydrochloride (unii: 8a9h4vk35z) (tivozanib - unii:172030934t) - fotivda is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (rcc) following two or more prior systemic therapies. none. risk summary based on findings in animal studies and its mechanism of action, fotivda can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data on fotivda use in pregnant woman to inform the drug-associated risk. in embryo-fetal developmental studies, oral administration of tivozanib to pregnant animals during the period of organogenesis caused maternal toxicity, fetal malformations and embryo-fetal death at doses below the maximum recommended clinical dose on a mg/m2 basis (see data) . advise pregnant woman of the potential risk to a fetus. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the

সিঙ্গাপুর - ইংরেজি - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - gozetotide - injection, powder, lyophilized, for solution - gozetotide 25μg/vial

অস্ট্রেলিয়া - ইংরেজি - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - cephalonium dihydrate - misc. intra mammary - cephalonium dihydrate antibiotic active 89.9 g/kg - antibiotic & related - dairy cattle - non-lactating (dry) perio - bacteria

অস্ট্রেলিয়া - ইংরেজি - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - cephalexin as cephalexin monohydrate - oral tablet - cephalexin as cephalexin monohydrate antibiotic active 300.0 mg/tb - antibiotic & related - dog | bitch | castrate | puppy - infections of soft cutaneous tissue | infections of the digestive tract | infections of the respiratory tract | infections of the urinary tracts | osteomyelitis | acute respiratory infections | bronchiseptica | bronchitis | escherichia coli | group d streptococcus | klebsiella spp. | pharyngitis | pneumonia | proteus spp. | pseudomonas aeruginosa | staphylococcus spp. | tonsillitis